A C Rawstron
Overview
Explore the profile of A C Rawstron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Howard D, Munir T, McParland L, Rawstron A, Milligan D, Schuh A, et al.
Leukemia
. 2017 Mar;
31(11):2416-2425.
PMID: 28336937
ARCTIC was a multicenter, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated chronic lymphocytic leukemia (CLL). Conventional frontline therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). The...
2.
Munir T, Howard D, McParland L, Pocock C, Rawstron A, Hockaday A, et al.
Leukemia
. 2017 Feb;
31(10):2085-2093.
PMID: 28216660
ADMIRE was a multicenter, randomized-controlled, open, phase IIB superiority trial in previously untreated chronic lymphocytic leukemia. Conventional front-line therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). Initial evidence...
3.
Rawstron A, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al.
Leukemia
. 2015 Dec;
30(4):929-36.
PMID: 26639181
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for...
4.
Rawstron A, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H, et al.
Leukemia
. 2012 Oct;
27(1):142-9.
PMID: 23041722
Detection of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) is becoming increasingly important as treatments improve. An internationally harmonised four-colour (CLR) flow cytometry MRD assay is widely used...
5.
Owen R, Bynoe A, Varghese A, de Tute R, Rawstron A
Clin Lymphoma Myeloma Leuk
. 2011 Aug;
11(1):176-9.
PMID: 21856554
Histological transformation, typically to diffuse large B-cell lymphoma (DLBCL) is reported to occur in 5%-10% of patients with WM and recent studies have highlighted a possible aetiological role for the...
6.
Perez-Andres M, Paiva B, Nieto W, Caraux A, Schmitz A, Almeida J, et al.
Cytometry B Clin Cytom
. 2010 Sep;
78 Suppl 1:S47-60.
PMID: 20839338
A relatively high number of different subsets of B-cells are generated through the differentiation of early B-cell precursors into mature B-lymphocytes in the bone marrow (BM) and antigen-triggered maturation of...
7.
Vital E, Dass S, Rawstron A, Buch M, Goeb V, Henshaw K, et al.
Arthritis Rheum
. 2010 Feb;
62(5):1273-9.
PMID: 20131284
Objective: A proportion of patients with rheumatoid arthritis (RA) have disease that fails to respond to an initial cycle of rituximab. Using highly sensitive flow cytometry (HSFC), it has been...
8.
Shanafelt T, Ghia P, Lanasa M, Landgren O, Rawstron A
Leukemia
. 2010 Jan;
24(3):512-20.
PMID: 20090778
Chronic lymphocytic leukemia (CLL) and the other low-grade non-Hodgkin lymphomas are among the most common lymphoid malignancies. Recent studies suggest that more than 4% of the general population over age...
9.
McGonagle D, Tan A, Madden J, Rawstron A, Rehman A, Emery P, et al.
Rheumatology (Oxford)
. 2008 Feb;
47(4):552-3.
PMID: 18281368
No abstract available.
10.
de Tute R, Jack A, Child J, Morgan G, Owen R, Rawstron A
Leukemia
. 2007 Jul;
21(9):2046-9.
PMID: 17657223
No abstract available.